JNK inhibitor protects dopaminergic neurons by reducing COX-2 expression in the MPTP mouse model of subacute Parkinson's disease

J Neurol Sci. 2009 Oct 15;285(1-2):172-7. doi: 10.1016/j.jns.2009.06.034. Epub 2009 Jul 14.

Abstract

Increasing evidence suggests that inflammation may be involved in the loss of dopaminergic neurons in Parkinson's disease (PD). Among inflammatory molecules, COX-2, a key kinase for the inflammatory response, has been suggested to play an important role in dopaminergic neuron loss in PD. However, the upstream molecular pathways of COX-2 expression remain uncertain. In the present study, we investigated the role of c-Jun [1] N-terminal kinase (JNK) in the process of COX-2 expression in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of subacute PD. Our data showed that MPTP induced a transient JNK activation of dopaminergic neurons, upregulated COX-2 expression in dopaminergic neurons, and caused the loss of dopaminergic neurons. We found that inhibiting JNK with SP600125, a special inhibitor of JNK, reduced the levels of c-Jun phosphorylation, blocked p-c-Jun translocation from the cytoplasm to the nucleus in dopaminergic neurons of substantia nigra, mitigated the loss of dopaminergic neurons, and improved motor function in MPTP-induced PD in C57BL/6N mice. These results indicate that JNK signaling pathway may be the major upstream mediator of regulation of COX-2 expression induced by MPTP in vivo and inhibiting JNK activity may represent a new and effective strategy to PD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Animals
  • Anthracenes / pharmacology*
  • Cell Death / drug effects
  • Cell Death / physiology
  • Cyclooxygenase 2 / metabolism
  • Disease Models, Animal
  • Dopamine / metabolism*
  • Enzyme Inhibitors / pharmacology*
  • JNK Mitogen-Activated Protein Kinases / antagonists & inhibitors*
  • MAP Kinase Signaling System / drug effects
  • MAP Kinase Signaling System / physiology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Movement Disorders / drug therapy
  • Movement Disorders / physiopathology
  • Neurons / drug effects*
  • Neurons / physiology
  • Parkinson Disease / drug therapy
  • Parkinson Disease / physiopathology
  • Parkinsonian Disorders / chemically induced
  • Parkinsonian Disorders / drug therapy*
  • Parkinsonian Disorders / physiopathology
  • Phosphorylation / drug effects
  • Proto-Oncogene Proteins c-jun / metabolism
  • Random Allocation
  • Substantia Nigra / drug effects
  • Substantia Nigra / physiopathology

Substances

  • Anthracenes
  • Enzyme Inhibitors
  • Proto-Oncogene Proteins c-jun
  • pyrazolanthrone
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Ptgs2 protein, mouse
  • Cyclooxygenase 2
  • JNK Mitogen-Activated Protein Kinases
  • Dopamine